Poseida Therapeutics Inc

Poseida Therapeutics — Investor Day (February 2022)

180 slides from Poseida Therapeutics's investor day presentation, Feb 23, 2022

  1. Slide 1: The Next Wave of Cell and Gene Therapies with the Capacity to Cure

    The Next Wave of Cell and Gene Therapies with the Capacity to Cure R&D Day February 23, 2022 Exhibit 99.1

  2. Slide 2: Disclaimer

    Disclaimer | POSEIDA R&D DAY 2022 This presentation and any accompanying oral commentary contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and include, w

  3. Slide 3: R&D Day Agenda and Speakers

    Poseida Programs and Technologies R&D Day Agenda and Speakers | POSEIDA R&D DAY 2022 Welcome Introduction and Overview Platform Technologies Super PiggyBac® DNA Delivery System CAS-CLOVER™ Gene Editing Biodegradable Nanoparticle Delivery TSCM Phenotype in CAR-T The Importance of TSCM Stemness and Ou

  4. Slide 4: R&D Day 2022 - Eric Ostertag

    R&D Day 2022 Eric Ostertag, MD, PhD Founder & Executive Chairman

  5. Slide 5: On a Mission to Redefine Cell and Gene Therapy

    | POSEIDA R&D DAY 2022 On a Mission to Redefine Cell and Gene Therapy CELL THERAPY GENE THERAPY PLATFORMS & PARTNERSHIPS CAR-T Therapy Focusing on Fully Allogeneic CAR-T as the ‘Holy Grail’ in Oncology In Vivo Liver-Directed Gene Therapy with Non-Viral Biodegradable Nanoparticle Delivery Platform De

  6. Slide 6: Proprietary In-house Technology Platforms

    Proprietary In-house Technology Platforms for Gene Insertion, Gene Editing, and Gene Delivery Powerful Platform Technologies Drive Our Strategy | POSEIDA R&D DAY 2022 Individually or in combination, our core technologies enable us to engineer a portfolio of product candidates designed to overcome th

  7. Slide 7: Our Platform Technologies Have Broad Reach

    Various combinations our innovative platform technologies create unique opportunities across the cell and gene therapy landscape Our Platform Technologies Have Broad Reach | POSEIDA R&D DAY 2022 *Poseida has listed companies it believes are representative of those active in cell and gene therapy. CE

  8. Slide 8: Proprietary In-house Technology Platforms

    Proprietary In-house Technology Platforms for Gene Insertion, Gene Editing, and Gene Delivery Powerful Platform Technologies Drive Our Strategy | POSEIDA R&D DAY 2022 Individually or in combination, our core technologies enable us to engineer a portfolio of product candidates designed to overcome th

  9. Slide 9: PiggyBac: Versatility in DNA Delivery

    Enables DNA integration Non-viral gene insertion technology Works in a wide variety of cell types Multiple safety and cost benefits PiggyBac®: Versatility in DNA Delivery | POSEIDA R&D DAY 2022 Generating CAR-T Products with Desirable High Percentage of TSCM Cells Preferentially favors stem cell mem

  10. Slide 10: piggyBac: Wild Type vs. Super piggyBac

    piggyBac®: Wild Type (WT) vs. Super piggyBac® (SPB) | POSEIDA R&D DAY 2022 Note: No structure data for NTD G165S M282V N538K WT PB-DNA Transposome Neg (–) Neg (–) N538K N538K: Electrostatic stabilization in linker between DDBD and CRD G165S: Enhances DNA binding (H-bonds w/ PO4 and Adenine) G165S M2

  11. Slide 11: piggyBac: Wild Type vs. Excision-Only piggyBac

    WT PB-DNA Transposome piggyBac®: Wild Type (WT) vs. Excision-Only piggyBac® (PBx) | POSEIDA R&D DAY 2022 R372A K375A R372 & K375: Critical because of interaction with target DNA (H-bonds w/ PO4 in backbone) Structure from Chen et al. Nat Commun, 2020 Jul 10;11(1):3446 PBx mutations from Li et al. PN

  12. Slide 12: Proprietary In-house Technology Platforms

    Proprietary In-house Technology Platforms for Gene Insertion, Gene Editing, and Gene Delivery Powerful Platform Technologies Drive Our Strategy | POSEIDA R&D DAY 2022 Individually or in combination, our core technologies enable us to engineer a portfolio of product candidates designed to overcome th

  13. Slide 13: Cas-CLOVER: Ultra-Clean Gene Editing

    Cas-CLOVER™: Ultra-Clean Gene Editing | POSEIDA R&D DAY 2022 3’ 5’ 5’ 3’ Cas-CLOVER Gene Editing System Low-to-no off-target cutting High Editing Efficiency in resting T-cells resulting in high % of TSCM cells Ease of use/design Multiplexing ability High specificity Lower cost Potentially the Cleane

  14. Slide 14: Highly Efficient On-target Knock-out in P-BCMA-ALLO1

    Multiple products (10) were tested by NGS to determine editing (% Indels) at the TRBC1, TRBC2 and B2M sites Single step multiplexed editing is highly efficient: Editing at B2M and TRBC is >85% across multiple donors (by NGS) Functional protein knock-out confirmed by FACS, other functional assays Hig

  15. Slide 15: Cas-CLOVER: Low to No Off-Target Cutting

    Cas-CLOVER™: Low to No Off-Target Cutting | POSEIDA R&D DAY 2022 Guide-Seq Ampli-Seq No hits in oncogenes or tumor suppressors (COSMIC database) Captured 152 sites 19 Assayed 140 sites Off-target Site Editing Off-target Mutations Per Donor Captured and Validated OTE Sites Sites Captured in ≥ 2 Donor

  16. Slide 16: Cas-CLOVER: Fidelity in T Cells vs. Competing Technology

    Cas-CLOVER™: Fidelity in T Cells vs. Competing Technology | POSEIDA R&D DAY 2022 PD1 TRAC PD1+ TRAC PD1 B2M+ TRBC N = 1 N = 1 N = 2 N = 2 N = 8 Other studies examine few (10 to 25) candidate off-target sites1-3 Our Cas-CLOVER off-target study is ~10x broader and includes 8 donor lots WT CRISPR Low O

  17. Slide 17: Cas-CLOVER: Very Low Translocation Frequency vs. CRISPR

    Cas-CLOVER™: Very Low Translocation Frequency in T Cells vs. CRISPR | POSEIDA R&D DAY 2022 Other studies (CRISPR & TALENs): 4% cells have TRAC translocation (FISH) Qasim et al., Sci Trans Med. 2017 2-2.5% with TRAC-B2M translocation Giannoukos et al., BMC Genomics. 2018 Up to 2% with TRAC-CD52 trans

  18. Slide 18: Proprietary In-house Technology Platforms

    Proprietary In-house Technology Platforms for Gene Insertion, Gene Editing, and Gene Delivery Powerful Platform Technologies Drive Our Strategy | POSEIDA R&D DAY 2022 Individually or in combination, our core technologies enable us to engineer a portfolio of product candidates designed to overcome th

  19. Slide 19: Single Treatment Cures Utilizing In Vivo Gene Therapy Technologies

    OUR GOAL: Develop Single Treatment Cures Utilizing Our In Vivo Gene Therapy Technologies AAV (SPB-DNA) AAV (PB-DNA) VIRAL + Delivery: Moving Toward Non-Viral Biodegradable Nanoparticles | POSEIDA R&D DAY 2022 Nanoparticle (SPB – RNA) Nanoparticle (PB – DNA) NON-VIRAL + Potential for Single-Treatment

  20. Slide 20: General Mechanism of LNP Co-Delivery of RNA and DNA

    General Mechanism of LNP Co-Delivery of RNA and DNA | POSEIDA R&D DAY 2022 Endosome Escape NUCLEUS ENDO/LYSOSOME CYTOSOL SPB mRNA Translation ENDO/LYSOSOME Endosome Escape Plasmid-dependent Nuclear Import Nanoplasmid Transcription, Integration RNA-LNP DNA-LNP SPB Nuclear Translocation SPB SPB-mediat

  21. Slide 21: >3X More Potency Compared With Benchmark

    >3X More Potency Compared With Benchmark Poseida Biodegradable RNA LNP Works in Non-Human Primates | POSEIDA R&D DAY 2022 ~3X Cmax (0.25 mg/kg): ~1,500 ng/mL Mouse ~4X (bolus 0.35 mg/kg) NHP ~3X (infusion 0.25 mg/kg)

  22. Slide 22: Poseida Biodegradable RNA LNP is Well Tolerated

    Poseida Biodegradable RNA LNP is Well Tolerated | POSEIDA R&D DAY 2022 No meaningful elevation of liver enzymes 7 days following LNP treatment Rat NHP

  23. Slide 23: piggyBac Nanoparticle System can be Dosed Repeatedly

    piggyBac® Nanoparticle System can be Dosed Repeatedly | POSEIDA R&D DAY 2022 Repeat Dosing of DNA+SPB Dose 3 0.25 mg/kg DNA + 0.5 mg/kg SBP-5MeC Adult/WT Mice Nano.pB-HLP-fLuc2 Dose 1 Dose 2 NT-01-009-201 Repeat Dosing (Day 28) Sequential transposon + SPB results in essentially dose-proportional tra

  24. Slide 24: Working to Engineer Single-Treatment Cures for Cancer & Genetic Diseases

    Broad innovative genetic engineering technology platforms Novel fully allogeneic high-TSCM CAR-T approach as well as Autologous CAR-T targeting PSMA Gene therapy focus on single treatment cures with non-viral delivery and strategic partnership with Takeda Working to Engineer Single-Treatment Cures f

  25. Slide 25: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones | POSEIDA R&D DAY 2022 Dual P-CD19CD20-ALLO1 IND and Phase 1 Initiation 2023 P-MUC1C-ALLO1 Clinical Update in 2022 P-OTC-101 Gene Therapy Preclinical Data Updates Potential for Additional Strategic Partnerships P-PSMA-101 Clinical Updated in 1Q22 P-BCMA-ALLO1 Clinical

  26. Slide 26: The Importance of Stem Cell Memory (TSCM) Cells

    | POSEIDA R&D DAY 2022 The Importance of Stem Cell Memory (TSCM) Cells Postdoc in Dr. Restifo’s lab at National Cancer Institute Identified human T stem cell memory (TSCM) cells Pioneer in use of TSCM cells for adoptive immunotherapy Major contributor to understanding of TSCM biology Over 100 public

  27. Slide 27: The Importance of Stem Cell Memory T (TSCM) Cells

    The Importance of Stem Cell Memory T (TSCM) Cells Luca Gattinoni, MD Director of the Division of Functional Immune Cell Modulation Leibniz Institute for Immunotherapy (LIT)

  28. Slide 28: Adoptive Immunotherapy Strategies

    Adoptive Immunotherapy Strategies | POSEIDA R&D DAY 2022

  29. Slide 29: Not All T Cells are Created Equally

    Stem Cell Memory TSCM Cell LESS DIFFERENTIATED Self-renewing Long lived Multipotent Central Memory TCM Cell Effector Memory TEM Cell TEFF Cell MORE DIFFERENTIATED Terminal Effector Not All T Cells are Created Equally | POSEIDA R&D DAY 2022 Antigen Experienced T Cell Subsets TN Cell

  30. Slide 30: TSCM Cells Largely Display a Naïve-like Phenotype

    TSCM Cells Largely Display a Naïve-like Phenotype | POSEIDA R&D DAY 2022 Gattinoni et al. Nat Med 2011 CXCR3 and CD58 can also be used to identify human TSCM cells within naïve-like T cells

  31. Slide 31: CD19 CAR-modified TSCM Cells Mediate Long-lasting Antitumor Responses

    CD19 CAR-modified TSCM Cells Mediate Long-lasting Antitumor Responses Against ALL TSCM Are Key to CAR-T Efficacy in Pre-clinical Studies Sabatino et al., Blood 2016 | POSEIDA R&D DAY 2022

  32. Slide 32: P-BCMA-101 data shows correlation of TSCM and efficacy

    P-BCMA-101 data shows correlation of TSCM and efficacy: Preclinical: Barnett et al; Hermanson et al, Poseida (2016) 58th ASH Clinical: Spear et al, Poseida (2019) 4th CAR-TCR Summit TSCM is shown to correlate with CAR-T clinical response: Melenhorst et al, UPenn (2017) Pre-manufactured cells, 20th A

  33. Slide 33: Early Memory Gene-Signature Correlates with CAR-T Efficacy

    Early Memory Gene-Signature Correlates with CAR-T Efficacy | POSEIDA R&D DAY 2022 Deng Q et al., Nature Med 2020

  34. Slide 34: TSCM Clones Contribute to Circulating CAR T Cell Pools

    TSCM Clones Contribute Substantially to the Circulating CAR T Cell Pools, During Both Early Expansion and Long-term Persistence Self-renewal and Multipotency are Key to CAR-T Efficacy | POSEIDA R&D DAY 2022 Gattinoni et al., Nat rev cancer 2012 NCI/LIT unpublished

  35. Slide 35: TSCM Cells Maintained Following Yellow Fever Vaccination

    TSCM Cells are Stably Maintained for > 25 Years Following Yellow Fever Vaccination TSCM Are Key to CAR-T Duration of Response | POSEIDA R&D DAY 2022 Fuertes Marraco et al., Science TM 2015

  36. Slide 36: Metabolic Fitness is Key to CAR-T Duration of Response

    Low Glycolytic Metabolism and High Mitochondrial Respiratory Capacity are Associated with Long-lived Memory Cells TSCM Metabolic Fitness is Key to CAR-T Duration of Response | POSEIDA R&D DAY 2022 Sabatino et al., Blood 2016 | Sukumar et al., J Clin Invest 2013 | van der Windt et al., Immunity 2016

  37. Slide 37: Reduced Release of Inflammatory Cytokines

    Reduced Release of Inflammatory Cytokines by Allogeneic CD19 CAR-modified TSCM Cell Products TSCM Are the Key to CAR-T Safety | POSEIDA R&D DAY 2022 Sabatino et al., Blood 2016

  38. Slide 38: Delayed Kinetic and Milder Inflammatory Responses

    Delayed Kinetic and Milder Inflammatory Responses by Allogeneic CD19 CAR-modified TSCM TSCM Are the Key to CAR-T Safety | POSEIDA R&D DAY 2022 Standard CD19-CAR T Cells CD19-CAR TSCM-enriched cells Brudno et al. J Clin Oncol, 2016 NCI/LIT Unpublished

  39. Slide 39: piggyBac Preferentially Transposes TSCM Cell and Naïve Precursors

    % Transposed 60 40 20 0 TSCM Cell TCM Cell TEM Cell TEFF Cell Naïve T-Cell Lentivirus Transduces More Differentiated T-Cells In Preclinical Studies Poseida’s piggyBac® Preferentially Transposes TSCM Cell and Naïve Precursors | POSEIDA R&D DAY 2022 piggyBac % Transduced 60 40 20 0 TSCM Cell TCM Cell

  40. Slide 40: Poseida Products Closely Match a TSCM Phenotype

    TN TSCM TCM TEM TTE P-BCMA-101 CD45RA + + - - + + CD45RO - - + + - - CCR7 + + + - - + CD62L + + + - - + CD28 + + + +/- - + CD27 + + + +/- - + IL-7Ra + + + +/- - + CXCR3 - + + - - + CD95 - + + + + + CD11a - + + + + + IL-2Rb - + + + + + CD58 - + + + + + CD57 - - - +/- + - Naïve/TSCM TCM TEM TEFF P-BCM

  41. Slide 41: Allogeneic Products Have Final TSCM Percentages Reaching ~80%

    Allogeneic Product Have Final TSCM Percentages Reaching ~80% Poseida’s CAR-T Products are Comprised of a High-Percentage of TSCM Cells | POSEIDA R&D DAY 2022 % TSCM P-BCMA-ALLO1 Research (Day 13-15 Harvest) Top Donors Yield Highest Percentage TSCM HEALTHY DONOR LEUKAPHERESIS MANUFACTURING OF ALLOGEN

  42. Slide 42: TSCM Correlates with Best Responses and Superior Safety

    TSCM Correlates with Best Responses Can Persist In Vivo And Offers A Superior Safety Profile Efficacy, Durability and Safety of Poseida’s High-TSCM Auto Product P-BCMA-101 | POSEIDA R&D DAY 2022 TSCM in P-BCMA-101 is directly correlated with best responses in the clinic Long-term persistence of TSCM

  43. Slide 43: Importance of TSCM Metabolism in Tumor Microenvironment

    Oxidative phosphorylation avoids dependency on glucose and other metabolites that are lacking in the solid tumor microenvironment Carl June et al., Ideal Metabolic Signature of CAR-T cells ↑Persistence ↑ Central Memory ↑ SRC ↑ Mitochondrial biogenesis ↑ Oxidative metabolism CAR-specific activation B

  44. Slide 44: Importance of TSCM Trafficking in Solid Tumors

    Normal PBMC controls (N=2) P-PSMA-101 clinical products (N=6) The Importance of TSCM Trafficking for Clinical Efficacy in Solid Tumor Indications | POSEIDA R&D DAY 2022 Poseida CAR-T and TSCM express a variety of trafficking molecules May facilitate trafficking to marrow, tumor P-PSMA-101 robust cli

  45. Slide 45: Summary

    Summary TSCM is the most desirable cell type for creating CAR-T products Associated with best responses in the clinic Unprecedented duration of response in some patients Unique and potentially best-in-class safety profile A key to CAR-T success against solid tumor indications Poseida has a unique ma

  46. Slide 46: TSCM Based CAR-T Product Candidates

    TSCM Based CAR-T Product Candidates Matt Spear, MD Chief Medical Officer

  47. Slide 47: The Importance of Stem Cell Memory T Cells

    Stem Cell Memory TSCM Cell MORE DIFFERENTIATED LESS DIFFERENTIATED Products with High % of TSCM Cells STEMNESS MATTERS Strong correlation with best responses in the clinic More gradual tumor killing with less toxicity Better duration of response and potential for re-response TSCM engrafts in bone ma

  48. Slide 48: Cell Therapy Pipeline

    CAR-T for Oncology and Beyond Cell Therapy Pipeline | POSEIDA R&D DAY 2022 Indication Candidate Discovery Preclinical IND-Enabling Phase 1 Phase 2 CAR-T FOR ONCOLOGY MULTIPLE MYELOMA P-BCMA-ALLO1 P-BCMACD19-ALLO1 PROSTATE CANCER P-PSMA-101 P-PSMA-ALLO1 SOLID TUMOR P-MUC1C-ALLO1 Dual CAR (Undisclosed

  49. Slide 49: Cell Therapy Pipeline

    CAR-T for Oncology and Beyond Cell Therapy Pipeline | POSEIDA R&D DAY 2022 Indication Candidate Discovery Preclinical IND-Enabling Phase 1 Phase 2 CAR-T FOR ONCOLOGY MULTIPLE MYELOMA P-BCMA-ALLO1 P-BCMACD19-ALLO1 PROSTATE CANCER P-PSMA-101 P-PSMA-ALLO1 SOLID TUMOR P-MUC1C-ALLO1 Dual CAR (Undisclosed

  50. Slide 50: P-PSMA-101: PSMA Targeted CAR-T Cells for mCRPC

    P-PSMA-101: PSMA Targeted CAR-T Cells for Metastatic Castrate-Resistant Prostrate Cancer (mCRPC) | POSEIDA R&D DAY 2022 1https://globenewswire.com/news-release/2017/02/02/913304/0/en/Prostate-Cancer-Market-Study-2017-Market-Size-of-Prostate-Cancer-Drugs-to-7b-in-2016-from-2-5b-in-2011.html 2https://

  51. Slide 51: Susan Slovin, MD, PhD Biography

    | POSEIDA R&D DAY 2022 Professor of Medicine, Department of Medicine at Weill Medical College of Cornell University Attending Physician in the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center Medica

  52. Slide 52: Phase 1 Study of P-PSMA-101 CAR-T Cells in mCRPC

    Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Susan Slovin, MD, PhD Memorial Sloan Kettering Cancer Center, New York, NY

  53. Slide 53: P-PSMA-101 Overview

    Overview | POSEIDA R&D DAY 2022 P-PSMA-101 is made using a unique CAR-T platform that results in a product comprised of a high percentage of T stem cell memory (TSCM) cells that targets Prostate-Specific Membrane Antigen (PSMA) TSCM cells have bone marrow homing capability that may be particularly r

  54. Slide 54: piggyBac: Non-viral DNA Delivery System for High-TSCM CAR-T

    piggyBac®: A Non-viral DNA Delivery System That Creates High-TSCM CAR-T Products | POSEIDA R&D DAY 2022 TTAA ITR Insulator Promoter Poly(A) TTAA Insulator ITR Safety Switch CAR Molecule Selection Gene Non-viral gene insertion technology Enables efficient DNA integration & stable expression Multiple

  55. Slide 55: Phase 1 mCRPC Clinical Trial: P-PSMA-101-001

    Phase 1 mCRPC Clinical Trial: P-PSMA-101-001 | POSEIDA R&D DAY 2022 Enrollment Day 0 Leukapheresis Baseline assessments Safety, efficacy, and biomarker assessments Lymphodepletion P-PSMA-101 Infusion Week 2 Inpatient monitoring PD or 2 years to LTFU £ Week -8 Week -4 Days -5, -4, -3 P-PSMA-101 is an

  56. Slide 56: Demographics & Characteristics

    Demographics & Characteristics (Heavily Pretreated mCRPC Patients) | POSEIDA R&D DAY 2022 Parameter (n=14) Median (min, max) age, y 71 (57, 79) Median (min, max) time since diagnosis, y 6.4 (1, 23) ECOG (Baseline) PS, 0/1, n (%) 7 (50) / 7 (50) Median (min, max) prior regimens 6 (3, 15) LHRH agonist

  57. Slide 57: Marked Decreases in PSA and PSMA-PET SUVs

    Marked Decreases in Prostate Specific Antigen (PSA) and PSMA-PET SUVs​ High Rates of Anti-Tumor Activity Demonstrated with Multiple Methods | POSEIDA R&D DAY 2022 a Central or local results. b CTC0 (n=5) defined as patients with CTCs >0 at enrollment and CTC = 0 during a post-infusion CTC assessment

  58. Slide 58: PSA and CTC Response Rates

    PSA and Circulating Tumor Cells (CTC) Response Rates | POSEIDA R&D DAY 2022 PSA responses (n=14)a Response n (%) PSA response (≥30% decrease) 6 (42.9) PSA response (≥50% decrease) 5 (35.7) CTC0b 1d (20.0) CTCconvc 1e (20.0) a Central or local results. b CTC0 (n=5) defined as patients with CTCs >0 at

  59. Slide 59: Treatment-Emergent Adverse Events

    TEAEs (n=14)​ TRAEs (n=14) a Grade ≥3 events were 2 cases of macrophage activation syndrome/CRS, one fatal after non-compliance in follow-up. CRS was frequently associated with transaminitis and intermittently with ocular symptoms/inflammation. b Patient counted once for either term. ALT = alanine a

  60. Slide 60: Overall Survival

    Overall Survival Overall Survival (OS) | POSEIDA R&D DAY 2022

  61. Slide 61: PK, PSA, PSMA-PET Correlate in Response

    PK, PSA, PSMA-PET, FDG-PET, Bone Scan, and Pathology Correlate in Response Patient 220-003: Evidence of Near Complete Tumor Elimination | POSEIDA R&D DAY 2022 68Ga-PSMA-11 (PSMA-PET) FDG-PET Baseline Baseline 12 weeks 12 weeks Biopsy at week 10 of prior bone metastasis showed CAR-T cells, bone remod

  62. Slide 62: Pharmacokinetics: Consistently High Expansion

    Pharmacokinetics: Consistently High Expansion | POSEIDA R&D DAY 2022 Most patients have significant CAR-T cell expansion in peripheral blood to levels generally associated with efficacy in CAR-T products Many CAR-T products show peak expansion between 5-14 days P-PSMA-101 shows peak expansion betwee

  63. Slide 63: Summary & Conclusions

    Summary & Conclusions | POSEIDA R&D DAY 2022 This interim update shows the exceptional efficacy of novel anti-PSMA CAR-T-cell product P-PSMA-101 at very low doses induced durable biochemical, radiographic, and functional radiographic responses in heavily pretreated patients with mCRPC, including a p

  64. Slide 64: Acknowledgements

    With the greatest appreciation to the patients Acknowledgements P-PSMA-101-001 Investigators Memorial Sloan-Kettering Cancer Center Susan F. Slovin, M.D., Ph.D. City of Hope Tanya Dorff, M.D. Sarah Cannon Research Institute - HealthOne Denver Gerald Falchook, M.D. Dana-Farber Cancer Institute Xiao W

  65. Slide 65: TSCM Based Allogeneic CAR-T Platform and Product Candidates

    TSCM Based Allogeneic CAR-T Platform and Product Candidates Devon J. Shedlock, PhD Chief Scientific Officer, Cell Therapy

  66. Slide 66: TSCM are the Key to CAR-T Efficacy & Safety

    TSCM are the Key to CAR-T Efficacy & Safety | POSEIDA R&D DAY 2022 P-BCMA-101 data shows correlation of TSCM and efficacy: Preclinical: Barnett et al; Hermanson et al, Poseida (2016) 58th ASH Clinical: Spear et al, Poseida (2019) 4th CAR-TCR Summit TSCM is shown to correlate with CAR-T clinical resp

  67. Slide 67: The Importance of Stem Cell Memory T Cells

    The Importance of Stem Cell Memory T Cells (TSCM) Not All T Cells are Created Equally | POSEIDA R&D DAY 2022 Stem Cell Memory TSCM Cell MORE DIFFERENTIATED LESS DIFFERENTIATED Strong correlation with best responses in the clinic More gradual tumor killing with less toxicity Better duration of respon

  68. Slide 68: TSCM Potential to Engraft and Self-renew

    We Believe TSCM Hold the Potential to Engraft, Self-renew and Create Wave after Wave of More Differentiated Effector Cells with One Administration CAR-TSCM Prodrug is Ideal for Treating Solid Tumors Our product candidates are comprised of a high percentage of TSCM cells, which we believe hold the po

  69. Slide 69: Innovation in Allogeneic CAR-Ts

    TCR knock-out MHC I knock-out TSCM Cell Self-renewing Long lived Multipotent Stem Cell Memory Innovation in Allogeneic CAR-Ts TSCM-rich Allogeneic CAR-Ts Enabled by Poseida’s Technologies Cell Type Matters TSCM is the ideal cell type for CAR-T due to greater safety and durability piggyBac® is the id

  70. Slide 70: Poseida's Unique Allogeneic CAR-T Platform

    Preserve/improve high TSCM Optimized dosing regimens Healthy donor material Robust manufacturing Dramatic cost reductions Up to 100s of doses Our patented technology is designed to overcome the “Allo Tax” and significantly increase production yield while preserving desirable TSCM attributes of P-BCM

  71. Slide 71: Booster Molecule Technology Overcomes the Allo Tax

    Other CAR-T Approaches Suffer from Impaired Allogeneic Manufacturing Booster Molecule Technology Overcomes the “Allo Tax” Gene Editing of TCR Can Impair Allogeneic CAR-T Manufacturing Compared to Unedited CAR-T = “Allo Tax” Our patented technology is designed to overcome these limitations, and signi

  72. Slide 72: Preclinical Products Exhibit Favorable Expansion and Phenotype

    Increase Expansion of CAR-T >40 healthy donors screened >90% success in small scale production Clinical manufacturing with booster currently being optimized Preclinical Products Exhibit Favorable Expansion and Phenotype Booster in Action: Increased Expansion and High CAR-TSCM Top Quartile Donors Yie

  73. Slide 73: Allogeneic CAR-T Products Resemble TSCM Phenotype

    TN TSCM P-BCMA-ALLO1 TCM TEM TTE - - + + + - + - - + - - CD28 + + + + +/- - CD27 + + + + +/- - IL-7Ra + + + + +/- - CXCR3 - + + + - - CD95 - + + + + + CD11a - + + + + + IL-2Rb - + + + + + CD58 - + + + + + CD57 - - - - +/- + Adapted from Gattinoni et al. (2017) Nat. Med. Poseida products closely matc

  74. Slide 74: CAR-TSCM Multipotency and Persistence in Rechallenge Model

    Survivors are rechallenged on Day 28 and clear additional tumor cells CAR-TSCM Demonstrate Multipotency and Persistence in Tumor Rechallenge Model P-BCMA-ALLO1 Demonstrates Hallmarks of TSCM Cells In Vivo | POSEIDA R&D DAY 2022 Efficacy in Multiple Myeloma Cancer Model (RPMI-8226) Total tumor cleara

  75. Slide 75: P-BCMA-ALLO1 Phase 1 Clinical Trial

    Clinical Trial Sites Advocate Aurora – Tulio Rodriguez, MD University of Oklahoma – Carrie Yuen, MD UCSD – Caitlin Costello, MD UCSF – Nina Shah, MD Johns Hopkins – Syed Abbas Ali, MD University of Maryland – Mehmet Kocoglu, MD University of Chicago – Ben Derman, MD P-BCMA-ALLO1 Phase 1 r/r Multiple

  76. Slide 76: TSCM Trafficking in Solid Tumors

    Normal PBMC controls (N=2) P-PSMA-101 clinical products (N=6) TSCM Trafficking may be Important for Clinical Efficacy in Solid Tumors Poseida CAR-T and TSCM express a variety of trafficking molecules May facilitate trafficking to marrow, tumor P-PSMA-101 robust clinical activity against bone marrow

  77. Slide 77: P-MUC1C-ALLO1 Potent Activity Against Solid Tumors In Vivo

    Triple-negative Breast (MDA.MB.468) and Ovarian Cancer (OVCAR3) Models P-MUC1C-ALLO1 Potent Activity Against Solid Tumors In Vivo | POSEIDA R&D DAY 2022 Triple-Negative Breast Cancer Model Ovarian Cancer Model 100% Tumor Elimination After ~2 Weeks

  78. Slide 78: P-MUC1C-ALLO1 Phase 1 Clinical Trial

    P-MUC1C-ALLO1 Phase 1 Clinical Trial Phase 1 Trial Design Phase 1 dose-finding and expansion study in advanced treatment-resistant solid tumors, including but not limited to ovarian cancer, pancreatic cancer, breast cancer (TNBC), non-small cell lung cancer (NSCLC) and others solid tumors Open Label

  79. Slide 79: Biomarkers of Product Quality and Optimal Donors

    Few Known Correlates of Preclinical / Clinical Activity, OR Biomarkers of Optimal Healthy Donors Aiming to Better Understand Biomarkers of Product Quality Identify biomarkers that: Increase our knowledge of T cell fitness and function Predict the best donors and products Identify best healthy donors

  80. Slide 80: Stringent In Vivo Models Used to Measure Product Quality

    Stringent In Vivo Models Used to Measure Product Quality Positive Predictive Value of Allogeneic CAR-T Product Quality Efficacy in Multiple Myeloma Cancer Model (RPMI-8226) 100% Tumor Elimination After ~3 Weeks Capacity for tumor control determined in vivo at ‘stress’ CAR-T doses Stringent myeloma m

  81. Slide 81: Early Memory Cells Correlate with Antitumor Efficacy

    P-BCMA-ALLO1 Early Memory Cells Correlate with Antitumor Efficacy Presence of early memory cells significantly correlated with in vivo efficacy Inverse correlation between CD8+/ CCR7+/ CD27+/ CD62L+/ TCF7+ cells and tumor growth Also important: Viability of product post-thaw Functional capacity in s

  82. Slide 82: Healthy Donors Eligible for Clinical Lot Manufacture

    Healthy donors (>25) were screened for manufacturability and function (in vitro and in vivo tumor efficacy) Most donors (93%) met manufacturability criteria Of those, 74% (14 of 19) met activity release criteria and are eligible for clinical lot manufacture 50% of those (7 of 14) demonstrated comple

  83. Slide 83: Summary: TSCM-based Allogeneic CAR-T Platform

    Summary: Poseida TSCM-based Allogeneic CAR-T Platform CAR-TSCM are the key to efficacy and safety Prodrug is ideal for treating solid tumor indications Poseida’s unique technology enables fully allogeneic CAR-Ts rich in TSCM Booster molecule facilitates potentially 100s of doses from a single manufa

  84. Slide 84: Dual CAR Programs

    Dual CAR Programs @POSEIDA

  85. Slide 85: PiggyBac Cargo Capacity Enables Multiple Antigen Targeting

    Proof of Concept: PB Can Effectively Deliver Multiple Full-length CARs in Single Transposon System * Plus selection gene and marker gene 1 BCMA 2 BCMA PSMA 3 BCMA PSMA CD19 4 BCMA PSMA CD19 GD2 Large Cargo Capacity Increases Optionality and Enables the Next Wave of Opportunity PiggyBac’s Cargo Capac

  86. Slide 86: Multiple Antigen Targeting with Dual CAR

    Multiple Antigen Targeting with Dual CAR to Improve Efficacy Overcome single antigen loss (heme) CD19 CAR-T clinical trials: up to 40% of relapse is caused by loss of CD19 antigen 2. Target heterogeneous tumors (solid) Highly heterogeneous antigen expression may contribute to poor CAR-T clinical res

  87. Slide 87: Multiple Antigen Targeting by Combining CAR-T and TCR-T

    Multiple Antigen Targeting by Combining CAR-T and TCR-T Platforms piggyBac® can be leveraged to deliver CAR and TCR αβ in same product Over 90% of engineered T cells express both CAR and TCR POTENTIAL BENEFIT Enable engineered T cell to recognize both cell surface and intracellular antigen presented

  88. Slide 88: Dual CAR-T vs Single Tandem CAR

    Dual CAR-T vs Single Tandem PiggyBac Provides Competitive Advantage with Dual CAR Dual CAR is More Effective Than a Tandem CAR | POSEIDA R&D DAY 2022 We compared various formats of our single-domain VH binders: Single CAR Single Tandem CAR Dual CAR We have learned: A tandem CAR is sometimes better t

  89. Slide 89: CD19/CD20 Dual CAR for B Cell Malignancies & Autoimmune Diseases

    CD19/CD20 Dual CAR for B Cell Malignancies & Autoimmune Diseases CAR-T Killing of Lymphoma Tumor Cells (Raji; CD19+ and CD20+) Dual antigen targeting can increase efficacy CD19/CD20 Dual CAR-Ts kill (double positive target cells) better than either single CAR-T alone Quad-cistronic vector Fully allo

  90. Slide 90: Binder Mutagenesis and Library Screening Platform

    Capable of Improving Performance of any CAR Binder Binder Mutagenesis and Library Screening Platform | POSEIDA R&D DAY 2022 Powerful binder mutagenesis platform Capable of improving performance of any CAR binder Developed at Poseida In vivo screening used for final determination of lead/s Survival,

  91. Slide 91: Binder Enhanced Via Single Point Mutation

    Proof-of-concept: Binder Enhanced Via Single Point Mutation to Outperform Canonical FMC63 scFv Improved CD19 VH Binder Performance Binder mutagenesis significantly improved final product function in a lymphoma cancer model *Error bars represent mean of 5 mice + SEM Efficacy in Lymphoma Cancer Model

  92. Slide 92: Summary: Poseida Dual CAR-T Programs

    Summary: Poseida Dual CAR-T Programs PiggyBac’s large cargo capacity enables delivery of numerous therapeutic genes e.g., CAR, TCR, armor, safety switch, selection gene, etc. Multiple antigen targeting with Dual CAR-T or CAR-TCR cells can improve efficacy Overcome single antigen loss (heme malignanc

  93. Slide 93: Gene Therapy Product Candidates

    Gene Therapy Product Candidates Eric Ostertag, MD, PhD Founder & Executive Chairman

  94. Slide 94: In Vivo Gene Therapy for Rare Diseases

    In Vivo Gene Therapy for Rare Diseases Disruption in Gene Therapy Fully Integrating PiggyBac® integrates into DNA enabling the potential for single treatment cures Addressing Challenges of Viral Delivery piggyBac and Nanoparticle technology can address limitations of AAV Broad Application piggyBac c

  95. Slide 95: Changing the Game in Liver-Directed Gene Therapy

    AAV (SPB-DNA) AAV (PB-DNA) Viral Non-Viral Nanoparticle (SPB – RNA) Nanoparticle (PB – DNA) piggyBac+AAV followed by piggyBac+Nanoparticle Changing the Game in Liver-Directed Gene Therapy Liver Cell Replication Clearance of Majority of Non-integrated AAV Residual AAV Integrated Transposon AAV + pigg

  96. Slide 96: Takeda Collaboration Financial Terms

    Financial Terms $45 million cash up front and pre-clinical milestones could exceed $125 million in the aggregate $435 million in clinical development, regulatory and commercial milestones per program Tiered royalties on commercial sales Takeda responsible for research program costs Broad non-viral i

  97. Slide 97: In Vivo Liver-Directed Gene Therapy Pipeline

    In Vivo Liver-Directed Gene Therapy with Non-Viral Nanoparticle Delivery In Vivo Liver-Directed and HSC-Directed Gene Therapy Gene Therapy Pipeline Indication Candidate Discovery Preclinical IND-Enabling GENE THERAPIES GENE THERAPIES GENE THERAPIES Ornithine Transcarbamylase Deficiency (OTC) P-OTC-1

  98. Slide 98: Emerging Technologies

    Emerging Technologies Eric Ostertag, MD, PhD​ Founder & Executive Chairman

  99. Slide 99: P-OTC-101 for Ornithine Transcarbamylase Deficiency

    P-OTC-101 for Ornithine Transcarbamylase Deficiency Jack Rychak, PhD Vice President, Gene Therapy

  100. Slide 100: Ornithine Transcarbamylase (OTC) Deficiency

    Ornithine Transcarbamylase (OTC) Deficiency | POSEIDA R&D DAY 2022 X-linked metabolic liver disorder Most common urea cycle disorder subtype and most common cause of 'early onset' illness Causes hyperammonemia crises which may result in neurological impairment or death Dietary protein restriction &

  101. Slide 101: Early Onset/Severe OTC Deficiency: Major Unmet Need

    Early Onset/Severe OTC Deficiency: Major Unmet Need and Opportunity for Benefit | POSEIDA R&D DAY 2022 1 day 7 days 1 mo 6 mos 2 yrs 7 yrs 30 yrs Neonatal/Early Onset (≤30 days after birth) Later Onset (1 mo – 16 years) Females vs. Males 1 Brassier et al., Orphanet Journal of Rare Diseases , 2015 (F

  102. Slide 102: P-OTC-101

    P-OTC-101 | POSEIDA R&D DAY 2022 Hepatocellular Replication Clearance of Majority of Non-integrated AAV Residual AAV Integrated Transposon OTC AAV + SPB mRNA LNP Biodegradable nanoparticle transiently delivers Super piggyBac® transposase (SPB) Rapid and stable integration of functional OTC gene into

  103. Slide 103: Standard AAV Approach Insufficient to Rescue Severe Phenotype

    Standard AAV Approach is Insufficient to Rescue Severe Phenotype Following Neonatal Treatment | POSEIDA R&D DAY 2022 0 Days after birth 46 mOTC shRNA Hyperammonemia AAV hOTC 1 Experimental Design SPFash treated on day=1 of life with 2E13 vg/kg of hOTC-AAV Mice challenged with shRNA (against mouse OT

  104. Slide 104: P-OTC-101 Enables Single Treatment Cure of OTC Disease Model

    P-OTC-101 Enables Single Treatment Cure of OTC Disease Model | POSEIDA R&D DAY 2022 ~56% OTC piggyBac® LNP + hOTC-AAV + <3% OTC hOTC-AAV 2E13 vg/kg hOTC-AAV +/- 0.2 mg/kg piggyBac transposase mRNA LNP administered on day=1 of life to spfash mice IHC for glutamine synthetase (pink) human OTC (brown)

  105. Slide 105: P-OTC-101 Enables Single Treatment Cure of OTC Disease

    P-OTC-101 Enables Single Treatment Cure of OTC Disease | POSEIDA R&D DAY 2022 Integrated copies in liver measured by ddPCR on day 83 post-treatment hOTC mRNA in liver measured by qRT-PCR on day 83 post-treatment Urinary orotic acid measured by LC-MS/MS on day 35 Plasma ammonia measured by clinical c

  106. Slide 106: piggyBac Reduces Therapeutic AAV Dose

    piggyBac® Reduces Therapeutic AAV Dose by Order(s) of Magnitude | POSEIDA R&D DAY 2022 + 0.5 mg/kg SPB-LNP 0.5 mg/kg LNP + hOTC_AAV administered on day=1 of life to spfash mice Survival Plasma Ammonia + 0.5 mg/kg SPB-LNP AAV alone Plasma ammonia measured by clin. chemistry analyzer on day 77 post-tr

  107. Slide 107: Transient mRNA Expression of piggyBac Transposase

    Transient mRNA Expression of piggyBac® Transposase from Biodegradable Nanoparticle | POSEIDA R&D DAY 2022 piggyBac transposase (SPB) expression in liver measured by ELISA in WT mice Cationic lipid concentration in liver measured by LC-MS/MS (0.5 mg/kg) in WT mice 3.5E13 vg/kg hOTC-AAV +/- 2 mg/kg tr

  108. Slide 108: Transgene Activity is Responsive to LNP Dose

    Transgene Activity is Responsive to LNP Dose | POSEIDA R&D DAY 2022 LNP Dose (mg/kg mRNA) hOTC-Expressing Hepatocytes Urinary Orotic Acid hOTC-AAV + SPB transposase mRNA LNP administered on day=1; OTC expression and urinary orotic acid measured on day = 83 Dose-proportional increase in hepatocytes e

  109. Slide 109: Summary and Conclusions

    Summary and Conclusions | POSEIDA R&D DAY 2022 Single treatment of hybrid piggyBac® AAV+LNP enables cure in mouse model of severe OTC Disease piggyBac® hybrid LNP/AAV approach reduces required AAV dose for therapeutic efficacy by order(s) of magnitude The piggyBac® System likely may be used with any

  110. Slide 110: P-FVIII-101 for Hemophilia A

    P-FVIII-101 for Hemophilia A Jack Rychak, PhD Vice President, Gene Therapy

  111. Slide 111: Hemophilia A

    Hemophilia A | POSEIDA R&D DAY 2022 X-linked bleeding disorder caused by deficiency in factor VIII Large cDNA (~7.1 kb) and complex protein Causes frequent bleeding episodes FVIII activity correlates with the severity of the disease ClassificationFVIII Activity Relative Incidence Severe <1% 50% Mode

  112. Slide 112: P-FVIII-101

    P-FVIII-101 | POSEIDA R&D DAY 2022 Biodegradable lipid nanoparticles (LNPs) deliver Super piggyBac transposase (SPB) and FVIII transposon (therapeutic transgene) No known cargo capacity limits Stable integration of functional human FVIII gene into genome Durable FVIII expression in growing liver Pos

  113. Slide 113: FVIII Activity in Juvenile HemA Mouse

    FVIII Activity in Juvenile HemA Mouse Dual-LNP co-administered as single dose IV to juvenile Hem A mice (n=7) 0.25 mg/kg Transposon (DNA) 0.50 mg/kg Transposase (mRNA) FVIII activity measured (tail vein collection) in 4-week intervals Therapeutic (25-83%) levels of FVIII activity observed Durable FV

  114. Slide 114: Durable Expression of Human FVIII in Neonatal Mice

    Dual-LNP co-administered as single dose IV to neonatal (day 1 of life) healthy BALB/C mice (n=6-9) 0.25 mg/kg Transposon (DNA) 0.50 mg/kg Transposase (mRNA) Human FVIII expression (protein concentration) measured by ELISA bi-weekly Durable expression of human FVIII maintained over 5 months Durable E

  115. Slide 115: Supraphysiological FVIII Expression at Low Doses

    In-progress study evaluating ongoing FVIII transposon and SPB transposase sequence optimization Dual-LNP co-administered as single dose IV to neonatal (day 1 of life) healthy BALB/C mice (n=4) 0.25 mg/kg Transposon (DNA) 1.0 mg/kg Transposase (mRNA) Genome integration with piggyBac® enables massivel

  116. Slide 116: Dual LNP piggyBac System Can be Repeatedly Dosed

    Dual LNP piggyBac® System Can be Repeatedly Dosed | POSEIDA R&D DAY 2022 Dose 1 Dose 3 Dual LNP, Repeat Dosing Dose 2 WT mice administered dual LNP with reporter (luciferase) transgene Controllable, dose-responsive pharmacology observed SPB transposase can be administered separately from transposon

  117. Slide 117: Summary

    Summary | POSEIDA R&D DAY 2022 P-FVIII-101 (fully biodegradable nanoparticle delivery) can achieve >100% of normal FVIII levels and durable expression with a single administration in a preclinical model. The biodegradable nanoparticle + Super piggyBac® DNA Delivery System may overcome the limitation

  118. Slide 118: Development of a Site-Specific Super piggyBac Transposition System

    Development of a Site-Specific Super piggyBac® Transposition System (ssSPB) Blair Madison Vice President, Genetic Engineering

  119. Slide 119: The Next Wave in Gene Therapy: Site-specific Transposition

    The Next Wave in Gene Therapy: Site-specific Transposition | POSEIDA R&D DAY 2022 A site-specific piggyBac® platform would be revolutionary: Superb genotoxicity safety profile Enables simultaneous cargo knock-in and gene knock-out Programmability for targeting any site in the genome Simplicity: 2-co

  120. Slide 120: piggyBac: A Versatile DNA Delivery System for Gene Therapy

    piggyBac®: A Versatile DNA Delivery System for Developing Gene Therapy Products | POSEIDA R&D DAY 2022 Non-viral gene insertion technology Enables DNA integration and stable expression High efficiency (Super piggyBac) Very large cargo capacity (~200 kB!) Works in a wide variety of cell types Multipl

  121. Slide 121: piggyBac: Wild Type vs. Super piggyBac

    piggyBac®: Wild Type (WT) vs. Super piggyBac® SPB | POSEIDA R&D DAY 2022 Note: No structure data for NTD G165S M282V N538K WT PB-DNA Transposome Neg (–) Neg (–) N538K N538K: Electrostatic stabilization in linker between DDBD and CRD G165S: Enhances DNA binding (H-bonds w/ PO4 and Adenine) G165S M282

  122. Slide 122: Excision-Only Transposase

    WT PB-DNA Transposome R372A K375A R372 & K375: Critical because of interaction with target DNA (H-bonds w/ PO4 in backbone) Structure from Chen et al. Nat Commun, 2020 Jul 10;11(1):3446 PBx mutations from Li et al. PNAS, 2013 Jun 18;110(25):E2279-87 R372 K375 CARGO ITR ITR “Cut” CARGO ITR ITR Genomi

  123. Slide 123: Generating a Site-specific Super piggyBac System

    Generating a Site-specific Super piggyBac® (ss-SPB) System | POSEIDA R&D DAY 2022 Super piggyBac® (SPB) Academic Attempts to Make Site-specific SPB 3-5-fold greater site-specificity Desirable profile but not site-specific >500-fold greater site-specificity Site-specific SPB Desirable Less Desirable

  124. Slide 124: Strategies for Site-specific Transposition

    Strategies for Site-specific Transposition | POSEIDA R&D DAY 2022 Previous fusions of PB with: Gal4 Zinc-finger TAL dCas9 Unimpressive Results: 3-5-fold enhancement at on-target site Predominantly off-target integration DBD TTAA DBD Target DNA CARGO DNA PB-DBD Fusion PB Transposase-DNA-binding-domai

  125. Slide 125: The Poseida Strategy

    The Poseida Strategy | POSEIDA R&D DAY 2022 Results: First demonstrated rescue of integration-defective PBx mutant Unprecedented level of site-specificity: >500-fold with SSv7 Data here are from un-optimized SPB fusion protein Our Strategy Exploit new structure data Computational modeling Iterative

  126. Slide 126: Off-target Tolerance of SSv6-PBx

    (SSv6-PBx) Off-target Tolerance of SSv6-PBx | POSEIDA R&D DAY 2022 Determining Specificity Mutate DBD target sequence to assay distinction of subtle alterations of 9-nt target Results show high level of discrimination for first-generation fusion Successive iterations/optimizations underway for incre

  127. Slide 127: Site-specific Transposition into Genome

    Site-specific Transposition into Genome off-target TTAA site mutated on-target TTAA site on-target TTAA site Genomic target Synthetic reporter delivered via lentivirus in HEK293T First assessed for SSv6-PBx Over 20% of cells GFP+ Mut. target (2 nt) On-target Off- target | POSEIDA R&D DAY 2022

  128. Slide 128: Building Upon Site-specificity: Obligate SPB Heterodimer

    Building Upon Site-specificity: Obligate SPB Heterodimer | POSEIDA R&D DAY 2022 Challenges with SPB-DBD Fusions Homodimeric nature of SPB complicates DBD fusion strategies; Only one DBD can bind target site Bipartite (1/2 site) recognition sequences enables equal and balanced binding “Splitting” the

  129. Slide 129: Key Characteristics of a SPB Obligate Heterodimer

    Key Characteristics of a SPB Obligate Heterodimer | POSEIDA R&D DAY 2022 Each SPB contains both positive (+) and negative (-) charges in the dimerization interface Engineer two new versions of SPB protein: SPB+ contains more (+) charge and SPB- contain more (–) charge Transposition only occurs when

  130. Slide 130: Rational Design of SPB Obligate Heterodimers

    Rational Design of SPB Obligate Heterodimers | POSEIDA R&D DAY 2022 Cryo-EM structure of piggyBac® used to identify residues involved in dimerization Residues mutated individually or in combination to make 7 versions each of SPB+ and SPB- SPB+ and SPB- versions tested for transposition activity indi

  131. Slide 131: Summary

    Summary | POSEIDA R&D DAY 2022 Poseida’s first generation Site-Specific SPB (ss-SPB) is a major technological advance Complete and unprecedented rescue of the integration-defective PBx mutation Structure-informed design of site-specific DNA binding motif fusion achieves >500-fold increase in site sp

  132. Slide 132: Liver-Directed Gene Editing with Cas-CLOVER

    Liver-Directed Gene Editing with Cas-CLOVER™ Blair Madison Vice President, Genetic Engineering

  133. Slide 133: Cas-CLOVER: Ultra-Clean Gene Editing

    Cas-CLOVER™: Ultra-Clean Gene Editing | POSEIDA R&D DAY 2022 3’ 5’ 5’ 3’ Cas-CLOVER Gene Editing System Low-to-no off-target cutting High Editing Efficiency in resting T-cells resulting in high % of TSCM cells Ease of use/design Multiplexing ability Lower cost Potentially the Cleanest Gene Editing P

  134. Slide 134: Inhibition of PCSK9 to Lower LDL-Cholesterol Levels

    Inhibition of PCSK9 to Lower LDL-Cholesterol Levels | POSEIDA R&D DAY 2022 Adapted from Dadu, R. T. & Ballantyne, C. M. Nat. Rev. Cardiol., 2014 PCSK9 protein is secreted by hepatocytes and binds to the LDL receptor, inducing its internalization and lysosomal degradation, resulting in increased circ

  135. Slide 135: Strategy for Targeting PCSK9 in Liver Hepatocytes

    Mouse Pcsk9 Gene Strategy for Targeting PCSK9 in Liver Hepatocytes | POSEIDA R&D DAY 2022 Hepatocytes 3’ 5’ 5’ 3’ Cas-CLOVER™ Gene Editing System Cas-CLOVER™ mRNA Pcsk9-targeting gRNAs Indel Loss of Function LNP Assay: Liver editing (NGS) Serum PCSK9 (ELISA)

  136. Slide 136: In Vitro Delivery of Cas-CLOVER mRNA Results in 100% Editing

    In Vitro Delivery of Cas-CLOVER™ mRNA Results in 100% Editing | POSEIDA R&D DAY 2022 Cas-CLOVER™ mRNA and gRNAs were encapsulated in single LNP with >96% encapsulation efficiency. Cas-CLOVER™ LNPs were used to transfect Hepa 1.6 cells. 100% editing with 500 ng RNA/LNP. Benchmark LNP used as POC 0 0.

  137. Slide 137: Efficient Cas-CLOVER Delivery and Editing with Biodegradable LNPs

    Efficient Cas-CLOVER™ Delivery and Editing with Poseida’s Biodegradable LNPs | POSEIDA R&D DAY 2022 Efficacy readouts show clear dose response effect. Cas-CLOVER™ works for in vivo liver editing with high efficiency Poseida LNP efficacy is maximal at 2 mg/kg (>60% indels) >80-85% decrease in PCSK9 p

  138. Slide 138: Cas-CLOVER Approaching Maximal Gene Editing in Hepatocytes

    Cas-CLOVER™ is Approaching Maximal Gene Editing in Hepatocytes | POSEIDA R&D DAY 2022 Endothelium Cholangiocytes Stellate Cells Kupffer Cells Hepatocytes Lymphocytes Liver biopsies consist of: Approximately 75% hepatocytes Remaining cells are stellate cells, Kupffer cells, cholangiocytes, endotheliu

  139. Slide 139: Cas-CLOVER-mediated Knock-Ins in iPSCs

    HBB, B2M, GAPDH, TRAC loci as examples Cas-CLOVER™-mediated Knock-Ins in Induced Pluripotent Stem Cells (iPSCs) | POSEIDA R&D DAY 2022 iPSCs Cas-CLOVER™ mRNA gRNAs HDR & Knock-in EP Assay: iPSC editing (ICE) iPSC knock-in (ddPCR) GFP pA RNA 3’ 5’ 5’ 3’ Cas-CLOVER™ Gene Editing System

  140. Slide 140: Cas-CLOVER is More Efficient Than WT CRISPR for Knock-Ins

    pDNA 10x 25x 30x pDNA 1x 1x More DNA = More Editing Brightfield GFP Cas-Clover Exon 1 HBB HBB HA Exon 2 Exon 3 Plasmid DNA HBBUBC-GFP HDR* UBC GFP bGHpA HBB HA Site-specific Insertion of a Large Transgene Cas-CLOVER™ is More Efficient Than WT CRISPR for Knock-Ins | POSEIDA R&D DAY 2022 UBC GFP bGHpA

  141. Slide 141: Ultra-High Efficiency Knock-Ins with Cas-CLOVER: GAPDH

    Ultra-High Efficiency Knock-Ins with Cas-CLOVER™: GAPDH | POSEIDA R&D DAY 2022 sgRNA Pair #1 sgRNA Pair #2 No sgRNA Flow Day 15 Day 7 Cas-CLOVER™ targeting at GAPDH yields ultra-high efficiency No selection/sorting Bi-allelic targeting evident Cas-CLOVER

  142. Slide 142: Efficient and Low Toxicity Knock-Ins: B2M

    HiFiCas9 vs. Cas-CLOVER™ yields similar efficiencies Cas-CLOVER™ exhibits significantly lower toxicity Highly Efficient and Low Toxicity Knock-Ins with Cas-CLOVER™: B2M | POSEIDA R&D DAY 2022 sgRNA Pair sgRNA_2 sgRNA_1 No sgRNA No sgRNA Cas-CLOVER HiFiCas9

  143. Slide 143: Efficient and Low Toxicity Knock-Ins: TRAC

    HiFiCas9 vs. Cas-CLOVER™ yields similar efficiencies Cas-CLOVER™ exhibits significantly lower toxicity Highly Efficient and Low Toxicity Knock-Ins with Cas-CLOVER™: TRAC | POSEIDA R&D DAY 2022 Cas-CLOVER HiFiCas9 sgRNA Pair No sgRNA sgRNA_2 sgRNA_1 No sgRNA

  144. Slide 144: Cas-CLOVER Role in Enhancing HDR

    Frequent Outperformance of Cas9 Suggests Role for Cas-CLOVER™ in Enhancing HDR Cas-CLOVER™ Monomer Binding to Donor Enhances Homology Directed Repair (HDR) | POSEIDA R&D DAY 2022 HiFi Cas9 Benchmark # of donor-targeting gRNAs (increasing CC binding) Cargo LHA RHA With additional donor-targeting gRNA

  145. Slide 145: Cas-CLOVER Enhances Nuclear Translocation

    Increased Episomal Expression Suggests Cas-CLOVER™ Enhances Nuclear Translocation Cas-CLOVER™ Monomer Binding to Plasmid Enhances Expression | POSEIDA R&D DAY 2022 GFP gRNAs gRNA concentrations N=2 Targeting gRNAs N=3 Targeting gRNAs N=4 Targeting gRNAs Cas-CLOVER™ + Plasmid-targeting gRNAs Episomal

  146. Slide 146: Positioning May Help Reduce Interference with HDR

    Positioning May Help Reduce Interference with HDR Process (e.g., 3’ strand invasion) Benefits of Positioning gRNA Binding Away from HDR Region | POSEIDA R&D DAY 2022 Proximal Mid BB Increasing HDR ssDNA circular donor with short dsDNA regions at gRNA target sites Cargo Increasing HDR Circular partia

  147. Slide 147: Enhanced HDR Only Observed with Cas-CLOVER

    Effects/benefit not observed with HiFiCas9, as expected Cutting of homology arms detrimental to HDR (HiFiCas9) Targeting Cas9 nuclease to donor plasmid ineffective or detrimental Enhanced HDR Only Observed with Cas-CLOVER™ Dimeric Platform | POSEIDA R&D DAY 2022 Mid BB Cargo Cas-CLOVER gRNAs targ Mi

  148. Slide 148: Summary

    Summary | POSEIDA R&D DAY 2022 Cas-CLOVER™ works for high-efficiency site-specific gene editing Cas-CLOVER™ can be delivered using Poseida’s proprietary biodegradable mRNA LNP Gene editing efficiency (>60%) and protein reduction (~85%) at Pcsk9 locus is approaching the theoretical maximum following

  149. Slide 149: Fully Allogeneic TCR-T Program

    Fully Allogeneic TCR-T Program Julia Coronella Vice President, Immuno-Oncology

  150. Slide 150: Platform Profile: Fully Allogeneic TCR-T

    Platform Profile: Fully Allogeneic TCR-Engineered T cells (TCR-T) | POSEIDA R&D DAY 2022 Poseida TCR-T Platform TCR-engineered T cells (TCR-T) express tumor-antigen-specific T cell receptors composed of α- and β-chains, which recognize antigen + MHC presented on the surface of target cells TCR-T acc

  151. Slide 151: TSCM Phenotype and Allogeneic TCR-T Features

    Adapted from Gattinoni et al. (2017) Nat. Med. Stemness Proliferative potential Lymphoid homing Antigen independence Lipid metabolism Low Dym Senescence Cytotoxicity Tissue tropism Antigen addiction Gylcolytic metabolism Oxidative stress TSCM Cell TCM Cell TEM Cell TEFF Cell TN Cell piggyBac® cargo

  152. Slide 152: Fully Allogeneic TCR-T Produced with Poseida Platform

    Fully Allogeneic TCR-T Produced with Poseida Platform Technology | POSEIDA R&D DAY 2022 Endogenous TCR Transgenic TCR Efficient endogenous TCR KO reduces the potential for alloreactivity and GvHD High TSCM % in the final product is associated with improved safety/durability​ Enhanced TCR avidity boo

  153. Slide 153: TCR-T for Immuno-Oncology (NY-ESO-1)

    TCR-T for Immuno-Oncology (NY-ESO-1)

  154. Slide 154: Optimized Allo NY-ESO-1 TCR-T Shows Robust In Vivo Activity

    Optimized Allo NY-ESO-1 TCR-T Shows Robust In Vivo Activity | POSEIDA R&D DAY 2022 In vivo efficacy: A375-NSG model TCR: 1G4 Does@3e6 Tetramer+ cells Proof-of-concept Allo TCR-T produced with optimized transposon demonstrated promising in vivo efficacy Poseida data Roth, T.L., et al. Nature 559, 405

  155. Slide 155: Approaches to Enhance TCR-T Efficacy

    Poseida Approaches to Enhance TCR-T Efficacy | POSEIDA R&D DAY 2022 Tg-TCR Dextramer CD4+ Regular TCR-T Poseida TCR-T CD8+ TRAC/TRBC DKO Prevents Mismatch Without Impairing T Cell Function TCR Avidity Enhancement Optimized TCR-T Exhibits Better Potency Optimized Allo TCR-T production process results

  156. Slide 156: TCR-T for Infectious Disease (COVID)

    TCR-T for Infectious Disease (COVID)

  157. Slide 157: Collaboration with TScan to Identify COVID-specific TCRs

    Collaboration with TScan to Identify and Sequence COVID-specific TCRs | POSEIDA R&D DAY 2022 EPITOPE PROTEIN TCR CLONE HLA KLWAQCVQL ORF1ab 63 A*02 YLQPRTFLL S 31 A*02 LLYDANYFL ORF3a 29 A*02 At TScan, an epitope library of SARS-CoV-2 was screened against PBMC from convalescent patients Three domina

  158. Slide 158: Characterization of Engineered Allo COVID TCR-T Product

    Characterization of Engineered Allo COVID TCR-T Product | POSEIDA R&D DAY 2022 Optimized engineering process yields final product with >80% expression of COVID TCR Optimized purification (chimeric TCRb chain of tgTCR) permits removal of unedited T cells Fully Allogeneic T cells with high expression

  159. Slide 159: Allo COVID TCR-T Are Polyfunctional, Specific and Potent

    Allo COVID TCR-T Are Polyfunctional, Specific and Potent | POSEIDA R&D DAY 2022 Effective and Specific Cytotoxic Response Against Cell Lines Presenting COVID Epitopes COVID-TCR T Polyfunctionality Robust induction of desired polyfunctional IFNg+ cells with viral peptide stimulation

  160. Slide 160: Allogeneic TCR-T In Vivo Efficacy Against COVID Peptide+ Cells

    Allogeneic TCR-T In Vivo Efficacy Against COVID Peptide+ Cells | POSEIDA R&D DAY 2022 POC for Poseida TCR-T platform for infectious disease Animal Model: COVID-epitope [KLW]-positive HEK293 Cells

  161. Slide 161: Dual CAR/TCR T cells

    Dual CAR/TCR T cells @POSEIDA

  162. Slide 162: Potential Therapeutic Benefits of CAR/TCR-T

    Potential Therapeutic Benefits of CAR/TCR-T | POSEIDA R&D DAY 2022 Enable engineered T cell to recognize both cell surface target and intracellular antigen presented by MHC TCR CAR Simultaneous Expression of CAR and TCR Poseida CAR/TCR-T: Best of Both Technologies TCR CAR Highly tumor-specific intra

  163. Slide 163: Allogeneic CAR/TCR-T Coexpression and Dual-Targeted Cell Killing

    Allogeneic CAR/TCR-T Coexpression and Dual-Targeted Cell Killing | POSEIDA R&D DAY 2022 BCMA_CAR NY-ESO_TCR BCMA_CAR-T NY-ESO_TCR-T CAR/TCR-T CAR/TCR-T Characterization CAR/TCR transposon comprised of both CAR and TCR gene into one expression cassette POC Allo CAR/TCR-T product exhibits high % CAR/T

  164. Slide 164: Summary

    Summary | POSEIDA R&D DAY 2022 Poseida’s TCR-T platform has numerous advantages, including a final product with a high percentage of stem cell memory (TSCM) CD4 and CD8 cells Ultra-high fidelity Cas-CLOVER™ allows multiplex editing (TCRA, TCRB, B2M), while retaining robust T cell function in vitro a

  165. Slide 165: CAR 3.0 – Using HSCs to Create CAR-based Cell Therapies

    CAR 3.0 – Using Hematopoietic Stem Cells (HSCs) to Create CAR-based Cell Therapies Nina Timberlake, PhD Director, Ex Vivo Cell Therapy

  166. Slide 166: CAR-HSC: The Next Wave in CAR Therapy

    Gene delivery to a relatively small number of input HSCs lowers costs while dramatic cellular expansion during differentiation minimizes dosing limitations of mature cells Robust Expansion 3 CAR gene delivery to the HSC makes CAR expression possible in any downstream cell type including T cells, NK

  167. Slide 167: Translating Platform Technologies to Modification of CD34+ Cells

    Translating Poseida’s Platform Technologies to Modification of CD34+ Cells | POSEIDA R&D DAY 2022 Successful Modification of CD34+ Cells with Various CAR Vectors Durable transgene expression in HSCs via piggyBac DNA Delivery System Efficient and high-fidelity KO using Cas-CLOVER™ Site-Specific Gene

  168. Slide 168: CAR-HSC Enables Multiple Pathways to Generate CAR-Effectors

    CAR-HSC Enables Multiple Pathways to Generate CAR-Effectors | POSEIDA R&D DAY 2022 Persistent Tumor Cell Killing Tumor Eradication & Relapse Control Continuous CAR-Effector Resupply via CAR-HSCs Targeted CAR-Effectors Differentiated in vivo Lifelong CAR-HSC Engraftment Ex vivo expansion to CAR-Effec

  169. Slide 169: CAR-HSCs Undergo Efficient Ex Vivo Selection, Expansion and Differentiation

    CAR-HSCs Undergo Efficient Ex Vivo Selection, Expansion and Differentiation | POSEIDA R&D DAY 2022 HSC piggyBac® CAR delivery Selected CAR-HSC Ex vivo Differentiated Pure CAR-NK ~700 CAR+ NK cells produced from 1 input HSC +MTX Selection Expansion and Differentiation CD56 CD56 MTX Selection Yields P

  170. Slide 170: Ex Vivo Differentiated CAR-NK Cells Exhibit Target-Specific Cytotoxicity

    Ex Vivo Differentiated CAR-NK Cells Exhibit Target-Specific Cytotoxicity | POSEIDA R&D DAY 2022 GFP BCMA CAR 78% CAR expression is effectively maintained during differentiation from CAR-HSCs to CAR-NK cells CAR-NK cells derived from CAR-HSCs have robust, tumor-specific killing capacity Tumor-specifi

  171. Slide 171: CAR-modified HSCs can Engraft, Persist and Form Effector Cells In Vivo

    CAR-modified HSCs can Engraft, Persist and Form Functional CAR-Effector Cells In Vivo | POSEIDA R&D DAY 2022 NSG Recipient Mice Busulfan Conditioning Humanized Mouse HSC Transplant Tumor Challenge

  172. Slide 172: Summary

    Summary | POSEIDA R&D DAY 2022 HSCs can be modified via the piggyBac® DNA Delivery System and used to produce a variety of CAR-Effector cells either in vivo or ex vivo In vivo CAR-HSC therapy could provide an inexhaustible supply of effector cells (CAR-T, CAR-NK and CAR-macrophage) to eradicate tumo

  173. Slide 173: R&D Day 2022 Closing Comments

    R&D Day 2022 Closing Comments Mark J. Gergen Chief Executive Officer

  174. Slide 174: Cell Therapy, Gene Therapy, Platforms & Partnerships

    CELL THERAPY GENE THERAPY PLATFORMS & PARTNERSHIPS CAR-T Therapy Focusing on Fully Allogeneic CAR-T as the ‘Holy Grail’ in Oncology In Vivo Liver-Directed Gene Therapy with Non-Viral Biodegradable Nanoparticle Delivery Platform Development, Partnerships and Collaboration 1 2 3 | POSEIDA R&D DAY 2022

  175. Slide 175: Allogeneic CAR-T Therapy for Oncology: Innovation in CAR-T

    TSCM Cell Self-renewing Long lived Multipotent Stem Cell Memory Allogeneic CAR-T Therapy for Oncology Innovation in CAR-T | POSEIDA R&D DAY 2022 Cell Type Matters TSCM is the ideal cell type for CAR-T due to greater safety and durability piggyBac® is the ideal non-viral gene insertion technology Ful

  176. Slide 176: In Vivo Gene Therapy for Rare Diseases

    In Vivo Gene Therapy for Rare Diseases Disruption in Gene Therapy | POSEIDA R&D DAY 2022 Fully Integrating PiggyBac® integrates into DNA enabling the potential for single treatment cures Addressing Challenges of Viral Delivery piggyBac and Nanoparticle technology can address limitations of AAV Broad

  177. Slide 177: Our Platform Technologies Have Broad Reach

    Various combinations our innovative platform technologies create unique opportunities across the cell and gene therapy landscape Our Platform Technologies Have Broad Reach | POSEIDA R&D DAY 2022 *Poseida has listed companies it believes are representative of those active in cell and gene therapy. CE

  178. Slide 178: Recent and Upcoming Milestones

    Recent and Upcoming Milestones | POSEIDA R&D DAY 2022 Dual P-CD19CD20-ALLO1 IND and Phase 1 Initiation 2023 P-MUC1C-ALLO1 Clinical Update in 2022 P-OTC-101 Gene Therapy Preclinical Data Updates Potential for Additional Strategic Partnerships P-PSMA-101 Clinical Updated in 1Q22 P-BCMA-ALLO1 Clinical

  179. Slide 179: Thank You

    Thank You | POSEIDA R&D DAY 2022 Our Special Guests Luca Gattinoni, MD Susan Slovin, MD, PhD Presenters Eric Ostertag, MD, PhD, Executive Chairman Matthew Spear, MD, Chief Medical Officer Devon Shedlock, PhD, CSO Cell Therapy Julia Coronella, PhD, Vice President Immuno-oncology Blair Madison, PhD, V

  180. Slide 180: Q&A

    Q&A The Next Wave of Cell & Gene Therapies with the Capacity to Cure

Poseida Therapeutics — Investor Day (February 2022) on 6ix